Award

Mechanisms relating PCSK9, inflammation and coronary endothelial dysfunction in HIV+ people

Description: HIV patients today experience an increasing burden of coronary artery disease (CAD). Two factors that potentially contribute to this increased risk in HIV are increased systemic inflammation and abnormal lipid metabolism. Lipid abnormalities are common in HIV infected individuals and may contribute to the increased cardiovascular risk in this population. HIV infection itself and its treatment with antiretroviral therapy can alter lipid metabolism and both are associated with higher LDL cholesterol and triglyceride levels. In addition, HIV infection itself is marked by increased systemic inflammation which correlates with the presence and extent of atherosclerosis, and although systemic inflammatory markers are reduced by ART, they are not reduced to normal levels. Although statins have anti-inflammatory properties and lower CV mortality in the general population, their use is often problematic in HIV+ people due to frequent drug interactions and concurrent liver disease. Importantly, CV event rates remain high in HIV+ patients on statin therapy and statins alone often do not adequately suppress inflammation in many patients. Therefore, new therapies are needed to target the fundamental underlying pathophysiologic mechanisms, namely increased inflammation and altered lipid metabolism contributing to HIV-mediated atherosclerotic disease. Inflammation contributes to the process of coronary endothelial dysfunction which itself plays a pivotal role in the development, progression, and clinical manifestations of CAD, and is a marker for sub-clinical disease, an independent predictor of adverse cardiovascular events, and a potential target for medical interventions. We recently developed noninvasive, reproducible MRI-based methods to measure coronary endothelial function (CEF) and systemic endothelial function (SEF). We propose a pilot clinical trial to test the hypothesis that an anti-inflammatory approach using an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9)--a protease that plays an important role in both cholesterol metabolism and systemic inflammation--improves abnormal CEF in patients with HIV. The proposed studies will provide novel much-needed mechanistic insight into the potential of anti-inflammatory strategies using the novel PCSK9 inhibitor (evolocumab) to improve coronary endothelial dysfunction, which inflammatory biomarkers herald the CEF/SEF response, and further delineate the relationship between PCSK9 levels and CEF.
Amount: $154,000
Funding type: research
Funder scheme: Grant-in-Aid
Start date: 2017-07-01
End date: 2019-06-30
Investigator: Allison Hays (lead)
Institutions: Johns Hopkins University, Johns Hopkins University School of Medicine
Field: Medicine
Funded outputs count: 3
Funder award ID: 17GRNT33670943
OpenAlex ID: G7774071245
2023 · Shashwatee Bagchi, Yaa A. Kwapong, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 6
2021 · Allison G. Hays, Michael Schär, et al. · Frontiers in Cardiovascular Medicine · 7
2018 · Micaela Iantorno, Sahar Soleimanifard, et al. · Atherosclerosis · 24